Neurosense Therapeutics is trading at $3.82, down 5.68%, with no clear company-specific catalyst identified for the October 2, 2026 decline.
- The investor-relations page lists September 28 and September 25 as the latest announcements; no October 2 item is shown.
- Major indexes are higher, so same-direction broad-market movement does not appear to explain the decline. Shares also fell in each of the six previous sessions listed in the supplied price context.